# Aurobindo Pharma share price today (Aurobindo Pharma Ltd, NSE: AUROPHARMA) > Aurobindo Pharma share price today: ₹1,796.30 at the NSE close on 18 November 2026, up 49.0% in a year. Aurobindo Pharma (NSE: AUROPHARMA) is worth ₹1,03,367 crore, trades at a P/E of 26.0 and has closed between ₹1,132.50 and ₹1,823.20 over the past 52 weeks. > Aurobindo Pharma Ltd's share price has risen faster than its earnings: +49.0% in a year, against +0.5% for earnings per share. AUROPHARMA · Pharma - Formulators · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Turning around, from the last 12 quarters - Price: ₹1,796.30 (+49.0% in a year) - P/E: 26.0× (higher than 97% of the last 11 years) - Revenue (Sep 2026): ₹10,263 Cr (+23.9% on a year ago) - Profit (Sep 2026): ₹1,124 Cr (+32.5% on a year ago) - Operating margin: 21.0% (+0.7 points on a year ago) - ROCE: 13%, FY26 - ROIC: 10.7%, against a 12.0% cost of capital: −1.3 points The main question: the share price moved +49.0% in a year while yearly earnings per share moved +0.5%. The difference came from the market paying a higher multiple. ## What is the Aurobindo Pharma share price today? Aurobindo Pharma Ltd's share price was ₹1,796.30 at the close on 18 November 2026. It has been rising for 49 weeks. That is 18.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,133 and ₹1,823, and at that close it sat 96% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 47 weeks in a row. Over the last 11 years the share price moved +145% while the NIFTY 500 moved +279%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Aurobindo Pharma this quarter? Three changes stood out: revenue up on a year earlier for 13 quarters in a row (every quarter we can compare), foreign funds (FIIs) raised their stake for 3 quarters in a row and indian funds and insurers (DIIs) cut their stake for 3 quarters in a row. 1. Revenue up on a year earlier for 13 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹10,263 crore, +23.9% on a year earlier. Why: Revenue rose because the US generics business sold more. Next results: check whether the partnered inhaler gets a full quarter of sales and whether the company starts making its own metered dose inhaler. From the earnings call on 5 Nov 2026. 2. Foreign funds (FIIs) raised their stake for 3 quarters in a row From 14% to 17.4% of the company by the September 2026 quarter. 3. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row From 27.7% to 24.4% of the company by the September 2026 quarter. ## What are Aurobindo Pharma's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Aurobindo Pharma reported revenue of ₹10,263 crore, up 23.9% from ₹8,286 crore a year earlier, and a profit of ₹1,124 crore, up 32.5% from ₹848 crore. ### Aurobindo Pharma results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹10,263 crore | ₹8,286 crore | +23.9% | | Profit | ₹1,124 crore | ₹848 crore | +32.5% | | Earnings per share | ₹19.57 | ₹14.61 | +33.9% | | Operating margin | 21.0% | 20.3% | +0.7 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Aurobindo Pharma's management discussed these results on a call held on 5 November 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the Aurobindo Pharma share price history? Aurobindo Pharma closed at ₹1,796.30 on 18 November 2026, up 49.0% from ₹1,205.90 a year earlier (21 November 2025) and up 180.9% over five years. Its highest weekly close since March 2016 was ₹1,823.20 on 13 November 2026. ### Aurobindo Pharma share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹1,827.50 | −1.7% | | 1 month ago · 19 Oct 2026 | ₹1,621.40 | +10.8% | | 6 months ago · 15 May 2026 | ₹1,511.80 | +18.8% | | 1 year ago · 21 Nov 2025 | ₹1,205.90 | +49.0% | | 3 years ago · 17 Nov 2023 | ₹1,007.35 | +78.3% | | 5 years ago · 18 Nov 2021 | ₹639.55 | +180.9% | | 10 years ago · 18 Nov 2016 | ₹722.40 | +148.7% | | Earliest weekly close in our records · 11 Mar 2016 | ₹732.45 | +145.2% | | Highest weekly close since March 2016, also the 52-week high · 13 Nov 2026 | ₹1,823.20 | −1.5% | | Lowest weekly close since March 2016 · 20 Mar 2020 | ₹346.70 | +418.1% | | 52-week low (weekly close) · 23 Jan 2026 | ₹1,132.50 | +58.6% | Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (567 weekly closes from 11 March 2016 to 18 November 2026.) ## What is the latest news on Aurobindo Pharma? 18 Nov 2026: Aurobindo Pharma closed at ₹1,796.30, down 1.7% on the week and up 10.8% on the month. 11 Nov 2026: ex-date for an interim dividend of ₹7 a share. ### Earlier - 5 Nov 2026: Aurobindo Pharma held its results call for July to September 2026. Management guided: Long-term operating margin to 22% in coming years via Lannett yields and utilisation plus China and biosimilars-biologics levers. - Results for July to September 2026: Revenue up 23.9% and profit up 32.5% on a year earlier. ## What dividend does Aurobindo Pharma pay? Aurobindo Pharma paid ₹7 a share in regular dividends in the 12 months to 18 November 2026 (1 payment), a yield of 0.39% at the ₹1,796.30 close on 18 November 2026. The last was an interim dividend of ₹7 a share, ex-date 11 November 2026. ### Aurobindo Pharma dividends since 1 April 2021 | Ex-date | Dividend per share | Type | Record date | | --- | --- | --- | --- | | 11 Nov 2026 | ₹7 | Interim | same day | | 8 Aug 2025 | ₹4 | Interim | same day | | 20 Feb 2024 | ₹1.50 | Interim | same day | | 20 Nov 2023 | ₹3 | Interim | same day | | 17 Feb 2023 | ₹3 | Interim | same day | | 6 Jun 2022 | ₹4.50 | Interim | 7 Jun 2022 | | 18 Feb 2022 | ₹1.50 | Interim | 21 Feb 2022 | | 17 Nov 2021 | ₹1.50 | Interim | 18 Nov 2021 | | 27 Aug 2021 | ₹1.50 | Interim | 30 Aug 2021 | Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 4 of 5 Of the last 5 financial years, years with an NSE dividend record Yes. Aurobindo Pharma Ltd paid out 7% of its profit as dividends in FY26, and it paid a dividend in 12 of its last 13 reported years. (From the NSE corporate-actions record, read 18 November 2026.) ## What did Aurobindo Pharma management say on the latest results call? On the call for July to September 2026, held on 5 November 2026, Aurobindo Pharma's management guided: Long-term operating margin to 22% in coming years via Lannett yields and utilisation plus China and biosimilars-biologics levers. > “By Aurobindo's standard, Lannett is doing well. Overall, whatever EBITDA we have, Lannett is very close to it, that is what I would say.” > Swami Iyer, on the call for July to September 2026 ### What management guided - China oral solid dosage break-even this quarter on expanding international supplies and customer conversion. - Operating cost base around ₹2,450 crore going forward with organic capital spending around $50 million per quarter for around $200 million yearly run-rate. - Europe sustained double-digit growth with Eugia double-digit quarterly growth and mix toward 50:50 US and rest-of-world by FY28-29. - Inhalation scale-up with Advair full benefit from next quarter and Raleigh lift in 6-9 months toward scaled 3-4 product portfolio by mid-2029. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/2786/Conference Call/CC-Nov26.pdf). (From the call for July to September 2026, 5 November 2026.) ## What to watch in Aurobindo Pharma's next results? When Aurobindo Pharma reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: China oral solid dosage to reach break-even this quarter - check loss reversal and supply momentum. Management raised each of these on the latest results call. - China oral solid dosage to reach break-even this quarter - check loss reversal and supply momentum. - Partnered inhaler full-quarter flow-through plus in-house metered-dose manufacturing start - verify United States benefit and Raleigh utilisation lift. - Pen-G scale-up toward next-year goal with price flow-through and anti-dumping progress - confirm operating leverage lift excluding incentive. ## Which stock lists is Aurobindo Pharma on? Aurobindo Pharma is on 5 of our India lists: Multibagger study list, Momentum stocks, 52 week high & low, Small & mid cap stocks and Pharma stocks. - [Multibagger study list Study stage: late](https://www.sectoralpha.in/multibagger-stocks-india) - [Momentum stocks Market value: ₹1,03,229 crore](https://www.sectoralpha.in/momentum-stocks-india) - [52 week high & low 52-week position: At 52-week high](https://www.sectoralpha.in/52-week-high-stocks-india) - [Small & mid cap stocks Size rank in India: 113](https://www.sectoralpha.in/small-cap-stocks-india) - [Pharma stocks Market value: ₹1,03,229 crore](https://www.sectoralpha.in/sectors/pharma-stocks-india) ## Is Aurobindo Pharma profitable? Aurobindo Pharma Ltd earned ₹1,124 Cr of net profit in the Sep 2026 quarter, +32.5% on the same quarter a year earlier. That is the 5th quarter in a row of profit growth. Full-year FY26 profit was ₹3,503 Cr. Over 10 years profit has grown 5.6% a year on average. The same quarter a year earlier earned ₹848 Cr. The Sep 2026 quarter's profit is 11.0% of that quarter's revenue. For the full year, FY26 profit was ₹3,503 Cr (+0.5% on the year before). Why profit moved: revenue changed +23.9% on a year earlier and the margin moved +0.7 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +16.8% and revenue +13.6%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Aurobindo Pharma make, and is it growing? Aurobindo Pharma Ltd reported ₹10,263 Cr of revenue in the Sep 2026 quarter, +23.9% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 9.3% a year on average. The last full year, FY26, came in at ₹33,653 Cr. The last four reported quarters add to ₹36,912 Cr. FY26 revenue was ₹33,653 Cr, +6.1% on the year before. Recent pace: the last four quarters grew +13.6% on average, against 9.3% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +13.5%, against +10.4% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +16.5%, against +5.5% a year (accelerating). ## How much of every ₹100 of sales does Aurobindo Pharma keep? Aurobindo Pharma Ltd's operating margin was 21.0% in the Sep 2026 quarter, 0.7 percentage points higher than the same quarter a year ago. Across 13 years it has been between 14.9% and 26.4%. The latest quarter is within that range. Why this happened. This is the capex inflection point: the money has been spent (five-year capex ₹17,506 Cr, capital work in progress ₹5,214 Cr) and ROCE is at 13%. As loss-making subsidiaries turn, two levers move together, EBITDA recovers the ₹200 Cr drag, and the effective tax rate falls from 31.9% toward the guided 28 to 29% because profits stop sitting in units with no tax credit. The model fails if the capacity lands into oversupplied markets: China profitability guidance was already cut to "positive". Why the margin moved: operating margin changed +0.7 percentage points on the year while gross margin changed +1.5 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Aurobindo Pharma's profit turning into cash? Over the last 3 years, 117% of Aurobindo Pharma Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹5,526 Cr of operating cash against ₹3,503 Cr of profit. After ₹2,686 Cr of spending on assets, ₹2,840 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 117% of profit came in as cash: the cash cycle got 30 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 1.5× depreciation over three years. The next section checks what that spending is building. ## Where does Aurobindo Pharma's cash go? Aurobindo Pharma Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 252 days in FY26, down from 282 days in FY21. It spent ₹7,434 Cr on assets over the last 3 years. Customers take 77 days to pay, and stock sits for 326 days on average. At FY26 sales of ₹33,653 Cr, each day of that cycle ties up about ₹92.2 Cr, so roughly ₹23,234 Cr is tied up in the business at any time. FY26: customers took 77 days to pay and stock sat for 326 days, about 10.7 months of sales sitting as stock, for a full cycle of 252 days, shorter than FY21's 282. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 326 days. Customers pay about 77 days after that. Suppliers are paid at 151 days. Together that makes the 252-day cycle. Spending on assets: ₹7,434 Cr over the last 3 years, against ₹4,949 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹5,214 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Aurobindo Pharma's P/E ratio, and how does it compare with its own history? Aurobindo Pharma Ltd's P/E is 26.0×, near the high end of its own history: higher than 97% of past readings. Its usual P/E (the middle reading) is 17.9×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why this happened. About $300M of annual US revenue at about 40% plant utilization; management will not guide on margin parity. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹69.05. Why the multiple is where it is: over the past year earnings per share moved +0.5% while the price moved +49.0%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +22.9% a year; about +5.5% a year came from earnings growth and about +17.4 percentage points from the multiple (the market paying more); over 10 years the price moved +9.5% a year; about +6.0% a year came from earnings growth and about +3.5 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the Aurobindo Pharma share price assume? Worked out from its price on 11 October 2026, Aurobindo Pharma Ltd's share price assumed profit growth of about 17.0% a year. Over the past 10 years its profit actually grew 5.6% a year. Today its P/E is 26.0×, higher than 97% of its own last 11 years. This is a one-day reading, taken on 11 October 2026. Every other number on this page, the multiple included, uses the latest price as of 18 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Aurobindo Pharma business getting better or worse? Aurobindo Pharma Ltd's business is turning around. Profit growth has swung from −3.6% at its recent low to +16.5%, improving for 4 quarters in a row, with ROCE steady at 15.7% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. ## What is the Aurobindo Pharma story, and has it been checked? Aurobindo Pharma Ltd's story is not scored yet against the checks our research set on 10 October 2026. Where it sits in its own cycle: mid expansion. Our read, 10 October 2026. From the numbers. From the price. Price stage 2, week 49, above its 200-day line, relative strength falling. Where they disagree. Earnings are only now starting to move (Q1 FY27 PAT +25%, about 16% on a core basis). Foreign shareholders have returned as customers in the last two quarters after a three-year rotation into domestic funds. What is not proven yet. Conversely, two more quarters of core PAT growth above 15% with China and Pen-G both reported profitable would show the premium is being earned. The test written in advance. The test written in advance. Guidance credibility, platform timelines keep slipping. Measured by: Guidance credibility, platform timelines keep slipping China and Pen-G reported EBITDA-positive in the Q2 FY27 call; no new timeline slips by the next result. What the company does. Q1 FY27 broke the flat run, revenue +16.3%, PAT +25.2%, but about 38% of the PAT gain was a doubling of other income; core growth was about 16%. FY27 guidance (EBITDA ₹8,000 Cr+, margin above 21%, tax down to 28 to 29%) implies EPS +17 to 26%; management has slipped seven of nine dated platform promises in a year. What the surface reading misses. The research reads it further: This is not a trough-margin artifact. What the surface reading misses. The surface reading is: ROCE 13% at the 10th percentile of its own history, a weaker business than it was. The research reads it further: The denominator ballooned ahead of the numerator. Fixed assets rose from ₹9,374 Cr (FY21) to ₹17,407 Cr (FY26) with another ₹5,214 Cr in capital work in progress, and five-year capex of ₹17,506 Cr absorbed 91% of operating cash. Much of that capital sits in platforms that are still loss-making or pre-revenue (Pen-G, China plant, biosimilars, TheraNym Unit 1 with revenue only from 2028). So low ROCE is part gestation, part a genuinely lower-return generic base after Revlimid exits. Lever 4 · Paying down debt: building. Europe crossed €1 billion in FY26 and grew 27 to 30% in the second half, at a 20% EBITDA margin; Q1 FY27 slowed to +11% in constant currency. What proves it keeps working: Europe scale-up with captive and China supply. It stops working if Europe constant-currency growth drops below 8% for two quarters or Europe EBITDA margin falls under 18%. Lever 3 · Management change: building. Captive 6-APA replaces imports: gross margin +153 bps YoY in Q1 FY27 and the plant turned EBITDA-positive in Q4 FY26 with ₹100+ Cr external sales. What proves it keeps working: Pen-G / 6-APA backward integration. It stops working if Gross margin slips back under 59% or the plant reports losses again because Chinese 6-APA pricing undercuts captive cost. Lever 1 · Operating leverage: building. About ₹200 Cr of FY26 EBITDA losses in Pen-G, China and new ventures; turning them to breakeven alone lifts EBITDA about 3% and cuts the tax rate. What proves it keeps working: New platforms move from losses to contribution. It stops working if Effective tax rate stays above 31% through Q3 FY27, showing the loss-making units have not turned. Lever 8 · Demerger or value unlock: building. About $300M of annual US revenue at about 40% plant utilization; management will not guide on margin parity. What proves it keeps working: Lannett acquisition, US scale and spare capacity. It stops working if Group operating margin falls below 20% in the first full Lannett quarters, showing the dilution is not being worked down. Sources: our stock research file (10 October 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Aurobindo Pharma management deliver what it promised? What Aurobindo Pharma Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Eugia FY27 Growth Outlook Not Reconciled · 5 November 2026. In Aug 2026, management explicitly guided Eugia to single-digit FY27 growth because of limited approvals and remediation work at Unit III. In Nov 2026, management described double-digit growth every quarter and full production capacity while also stating that prior guidance remained on track, without reconciling the materially different growth outlook. Eugia FY27 Growth Outlook Reversed · 6 August 2026. In the May 2026 call, management expected the base Eugia business to continue growing at a double-digit rate. In the August 2026 call, management revised this to single-digit growth because of limited new approvals and Unit 3 remediation; although a reason was provided, the revision was not reconciled with the prior outlook. China EBITDA Outlook Softened · 6 August 2026. In May 2026, management said China would contribute significantly in FY27 and that it was working toward a low double-digit EBITDA margin. In August 2026, management only said China should be positive, materially lowering the stated profitability expectation without explaining the change. Pen-G MIP and PLI Benefits Became Conditional · 6 August 2026. Earlier calls described the Pen-G minimum import price as an issued government policy and expressed confidence that the PLI payment would be received. In August 2026, management said it had not achieved the MIP or relevant status and treated both MIP and PLI as conditional, creating material uncertainty around benefits that had previously supported the Pen-G profitability outlook. Every quote above is taken word for word from the company’s own earnings calls. ## What is Aurobindo Pharma management's track record? Named promoters' challenge to SEBI's profit-deposit directive was dismissed by the High Court. The company says there is no operating or financial impact, which does not exempt promoter conduct under the management rule. The separate old liquor case is reported acquitted and is not used as a veto. 13.75% Promoter shares pledged Sources: - [aurobindo.com](https://www.aurobindo.com/api/uploads/conferencecalltranscripts/Aurobindo_Transcript_Q4FY26.pdf) - [nsearchives.nseindia.com](https://nsearchives.nseindia.com/corporate/AUROPHARMA_16052026214207_LtrToSEsOrderHighCourtSEBIPIT16052026.pdf) - [aurobindo.com](https://www.aurobindo.com/api/uploads/ShareholdingPattern30.06.2026.pdf) (Checked 14 October 2026.) ## How much does Aurobindo Pharma earn on its capital? Aurobindo Pharma Ltd earned a ROCE of 13% in FY26. That is up from a low of 9% in FY23. Its return on capital used (ROIC) is 1.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 10.4% net margin and 0.58× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 10.4% net margin × 0.58× asset turnover × 1.54× leverage (assets divided by equity) ≈ 9.3% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 10.7% − 12.0% = −1.3 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Aurobindo Pharma have too much debt? Aurobindo Pharma Ltd has total debt of ₹8,630 Cr against shareholder equity of ₹39,400 Cr as of Sep 2026, so its debt is 0.22× its equity, which is very little. Year by year, that ratio went from 0.12 in FY22 to 0.21 in FY26. So the returns on this page come from the business, not from borrowed money. Why this happened. Europe is the largest growth engine. Revenue grew 27% in Q3 FY26 and 30% in Q4 FY26, with EBITDA at 20% and management citing captive supply and lower third-party dependence. Q1 FY27 slowed to 11% in constant currency, consistent with the double-digit floor management guided for FY27. Second-order: the China tablet plant and in-house sourcing are the cost lever that keeps tender pricing profitable; competitors without captive supply bear the solvent and freight inflation management flagged. The remaining benefit is margin, not growth rate. ## What is the Aurobindo Pharma shareholding pattern? No group of Aurobindo Pharma Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved −0.8 points over the same period, to 24.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Why this happened. Captive 6-APA replaces imports: gross margin +153 bps YoY in Q1 FY27 and the plant turned EBITDA-positive in Q4 FY26 with ₹100+ Cr external sales. Over the last two years: Foreign institutions: +0.8 points over 8 quarters, to 17.4%; Domestic institutions: −0.8 points over 8 quarters, to 24.4%; Promoters: +0.1 points over 8 quarters, to 51.9%. ## How far is Aurobindo Pharma from balance-sheet trouble? For Aurobindo Pharma Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Aurobindo Pharma rank in its industry? 58.9 out of 100, rank 13 of 44 in Pharma - Formulators, with 100% of the evidence available. Aurobindo Pharma Ltd scores 58.9 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 13. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 18.9 + 13.3 + 10.6 + 16.1 = 58.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Aurobindo Pharma compared with? Aurobindo Pharma ranks 13 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 58.9 out of 100. 1. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · losing its lead · Most evidence points up · 78% evidence 75.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidence Capital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidence Valuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidence Relative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks ahead Exact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · leader · Most evidence points up · 75% evidence 72.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidence Capital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidence Valuation 10.0/20 · P/E 40.5× · PEG n/a · 15% evidence Relative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 75% evidence 68.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidence Capital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidence Valuation 6.5/20 · P/E 45.5× · PEG n/a · 50% evidence Relative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks ahead Exact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · losing its lead · Most evidence points up · 87% evidence 67.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidence Capital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidence Valuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidence Relative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks ahead Exact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 5. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · losing its lead · Most evidence points up · 65% evidence 66.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.8/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidence Valuation 10.1/20 · P/E 25.6× · PEG n/a · 50% evidence Relative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · quiet · Most evidence points up · 100% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidence Valuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidence Relative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%. 7. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Most evidence points up · 100% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidence Capital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidence Valuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidence Relative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidence Valuation 6.5/20 · P/E 44.8× · PEG n/a · 50% evidence Relative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · leader · Evidence leans up · 85% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidence Capital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidence Valuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidence Relative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks ahead Exact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · leader · Evidence leans up · 82% evidence 62.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidence Capital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidence Valuation 11.7/20 · P/E 33.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · losing its lead · Evidence leans up · 70% evidence 61.2 out of 100 Growth Capital Valuation Relative 12. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · turning · Evidence leans up · 75% evidence 59.2 out of 100 Growth Capital Valuation Relative 13. Aurobindo Pharma Ltd this page AUROPHARMA · leader · Evidence leans up · 100% evidence 58.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.9/35 · Revenue 13.5% · Profit 16.5% · Operating margin change 1 points · 100% evidence Capital efficiency 13.3/25 · ROCE 12.9% (year to Mar 2026) · Operating margin 21% · 100% evidence Valuation 10.6/20 · P/E 26× · PEG 1.27 · 100% evidence Relative strength 16.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 7.5% · Strength vs NIFTY 500 (same reading) 22.1% · 1 year 49% · 100% evidence · 12 of 12 weeks ahead Exact sum: 18.9 + 13.3 + 10.6 + 16.1 = 58.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 14. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · breaking out · Evidence leans up · 73% evidence 58.3 out of 100 Growth Capital Valuation Relative 15. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Evidence leans up · 90% evidence 57.2 out of 100 Growth Capital Valuation Relative 16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 75% evidence 56.8 out of 100 Growth Capital Valuation Relative 17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.0 out of 100 Growth Capital Valuation Relative 18. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · turning · Evidence leans up · 82% evidence 55.8 out of 100 Growth Capital Valuation Relative 19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · quiet · Evidence leans up · 90% evidence 55.2 out of 100 Growth Capital Valuation Relative 20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 83% evidence 54.7 out of 100 Growth Capital Valuation Relative 21. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Evidence leans up · 63% evidence 54.3 out of 100 Growth Capital Valuation Relative 22. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · breaking out · Evidence leans up · 90% evidence 54.1 out of 100 Growth Capital Valuation Relative 23. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · losing its lead · Evidence leans up · 75% evidence 53.3 out of 100 Growth Capital Valuation Relative 24. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 82% evidence 52.3 out of 100 Growth Capital Valuation Relative 25. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · breaking out · Evidence leans up · 90% evidence 51.5 out of 100 Growth Capital Valuation Relative 26. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Evidence leans up · 90% evidence 50.6 out of 100 Growth Capital Valuation Relative 27. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 68% evidence 49.1 out of 100 Growth Capital Valuation Relative 28. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 82% evidence 48.3 out of 100 Growth Capital Valuation Relative 29. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 45.8 out of 100 Growth Capital Valuation Relative 30. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.8 out of 100 Growth Capital Valuation Relative 31. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 74% evidence 42.8 out of 100 Growth Capital Valuation Relative 32. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · basing · Evidence leans down · 90% evidence 42.7 out of 100 Growth Capital Valuation Relative 33. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 90% evidence 41.5 out of 100 Growth Capital Valuation Relative 34. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.8 out of 100 Growth Capital Valuation Relative 35. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 90% evidence 38.9 out of 100 Growth Capital Valuation Relative 36. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · turning · Too little evidence to rank firmly · 52% evidence 37.8 out of 100 Growth Capital Valuation Relative 37. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 67% evidence 34.4 out of 100 Growth Capital Valuation Relative 38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · quiet · Most evidence points down · 100% evidence 34.2 out of 100 Growth Capital Valuation Relative 39. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Most evidence points down · 90% evidence 31.9 out of 100 Growth Capital Valuation Relative 40. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · breaking out · Most evidence points down · 100% evidence 30.4 out of 100 Growth Capital Valuation Relative 41. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · quiet · Most evidence points down · 100% evidence 27.9 out of 100 Growth Capital Valuation Relative 42. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · basing · Most evidence points down · 100% evidence 22.7 out of 100 Growth Capital Valuation Relative 43. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.4 out of 100 Growth Capital Valuation Relative 44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence 38.3 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Aurobindo Pharma in size? Aurobindo Pharma is the 7th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Dr Reddys Laboratories, Cipla and Mankind Pharma. Just below it: Lupin, Glenmark Pharmaceuticals and Alkem Laboratories. ### Pharma - Formulators companies close in size 1. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) ₹1,16,787 crore 2. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) ₹1,14,478 crore 3. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) ₹1,08,424 crore 4. Aurobindo Pharma Ltd ₹1,03,355 crore 5. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) ₹90,174 crore 6. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) ₹74,679 crore 7. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ₹62,443 crore [All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies) ### Companies close in size in other industries 1. [Hero MotoCorp Ltd](https://www.sectoralpha.in/stocks/hero-motocorp-ltd) ₹1,05,145 crore · Auto - 2 & 3 Wheelers 2. [United Spirits Ltd](https://www.sectoralpha.in/stocks/united-spirits-ltd) ₹1,04,811 crore · Alcoholic Beverages 3. Aurobindo Pharma Ltd ₹1,03,355 crore 4. [Indus Towers Ltd](https://www.sectoralpha.in/stocks/indus-towers-ltd) ₹1,03,310 crore · Telecom Services 5. [FSN E-Commerce Ventures Ltd](https://www.sectoralpha.in/stocks/fsn-e-commerce-ventures-ltd) ₹1,00,837 crore · New age - Platform - E-Retail ## What else do people ask about Aurobindo Pharma? ### What is Aurobindo Pharma's share price today? Aurobindo Pharma Ltd's share price is ₹1,796.30, +49.0% over the past year. The whole company is worth ₹1,03,367 Cr on the market. In the last 52 weeks it traded between ₹1,133 to ₹1,823; today it is 96% of the way up from the low, 18.0% above its 200-day average (as of 18 November 2026). ### What were Aurobindo Pharma's latest quarterly results? Aurobindo Pharma Ltd reported revenue of ₹10,263 Cr and net profit of ₹1,124 Cr for the Sep 2026 quarter. Revenue rose 23.9% and profit rose 32.5% compared with a year earlier. Earnings per share were ₹19.57. The operating margin was 21.0%, 0.7 percentage points higher than a year earlier (as of 18 November 2026). ### What is Aurobindo Pharma's market cap? Aurobindo Pharma Ltd's market capitalisation is ₹1,03,367 Cr at a share price of ₹1,796.30. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### How is Aurobindo Pharma performing? Aurobindo Pharma Ltd's share price has been rising for 49 weeks. In its latest quarter, revenue rose 23.9% and profit rose 32.5% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 47 weeks running (as of 18 November 2026). ### Will Aurobindo Pharma's share price go up? This page does not forecast Aurobindo Pharma Ltd's share price. What it shows instead: the share price is ₹1,796.30, and it has been rising for 49 weeks. Its P/E of 26.0× is higher than 97% of its own last 11 years (as of 18 November 2026). ### Who owns Aurobindo Pharma? Promoters own 51.9% of Aurobindo Pharma Ltd, foreign institutions 17.4%, domestic institutions 24.4%, the public 6.3% and the government 0.1% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 18 November 2026). ### Does Aurobindo Pharma have too much debt? No, Aurobindo Pharma Ltd has little debt: its debt is 0.21× its equity, and its operating profit is 18 times its interest bill. FY26 borrowings were ₹8,073 Cr against equity of ₹37,891 Cr. So the returns on this page come from the business, not borrowed money (as of 18 November 2026). ### Where is Aurobindo Pharma in its business cycle? Aurobindo Pharma Ltd's FY26 operating margin was 20.4%, against a 13-year range of 14.9% to 26.4%. The latest quarter was 21.0%, the middle of its own range, neither a peak nor a low. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the Aurobindo Pharma story? The main question: the share price moved +49.0% in a year while yearly earnings per share moved +0.5%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is Aurobindo Pharma a stock worth studying right now? What the numbers show: Aurobindo Pharma Ltd's share price has risen faster than its earnings: +49.0% in a year, against +0.5% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ### Is there a Aurobindo Pharma share price forecast for 2026? What management itself guided: Long-term operating margin to 22% in coming years via Lannett yields and utilisation plus China and biosimilars-biologics levers. ### Where does this page get Aurobindo Pharma's management information? From Aurobindo Pharma's results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. ## Lists - Multibagger study list: https://www.sectoralpha.in/multibagger-stocks-india - Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india - 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india - Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india - Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india This is research, not advice. We’re not SEBI-registered.